Omeros Corp. has received Orphan Drug Designation from the FDA for OMS824, its phosphodiesterase 10 (PDE10) inhibitor for the treatment of Huntington’s disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington’s disease and schizophrenia. OMS824’s Phase I results in healthy subjects demonstrated that it is well tolerated and suggest that it has a better clinical therapeuti...